Aug 12, 2020
Resoundant Expands Its Research Services Footprint
Jun 17, 2020
Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH
May 07, 2020
Galmed Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on Thursday May 14
Mar 05, 2020
Zydus Announces World's First Drug for the Treatment of Non-Cirrhotic NASH
Mar 05, 2020
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12
Mar 03, 2020
MAX BioPharma Announces Key Update to its Liver Fibrosis Program Showing Efficacy of an Oxysterol Lead Drug Candidate in Inhibiting NASH in a Humanized Mouse Model
Feb 25, 2020
Clinical Study Supports Bergacyn® for Liver and Vascular Health
Feb 12, 2020
Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia
Feb 06, 2020
ProSciento and Nordic Bioscience Form Strategic Partnership to Develop Translational Biomarkers for Nonalcoholic Steatohepatitis (NASH)
Jan 28, 2020
Enzychem Lifesciences Appoints Dr. Michael Charlton To Its Scientific Advisory Board
Jan 13, 2020
Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients
Dec 16, 2019
Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH
Nov 21, 2019
Elysium Health(TM) Announces Clinical Trial to Explore the Effect of Basis(TM) on Liver Fat Accumulation in Healthy Adults with Fatty Liver (NAFL)
Nov 21, 2019
Enzychem Lifesciences Presents EC-18 NASH Development Update at The Liver Meeting 2019
Nov 19, 2019
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Nov 13, 2019
AMRA Medical Abstract Selected for AASLD's "Best of The Liver Meeting" Showcase
Nov 09, 2019
qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Crucial Histopathological Features
Oct 30, 2019
Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6
Oct 30, 2019
PharmaNest Announces New Adult and Pediatric NASH Data to Be Presented at the AASLD - Liver Meeting® 2019
Oct 22, 2019
HighTide Therapeutics Announces Completion of Enrollment in Phase 2a NASH Study of HTD1801